Nicole Murphy is Head of Pharm Ops and Tech at BIOGEN INC. (BIIB). They have made 1 open-market trade across 1 company since 2026, most recently 2026-02-12.
CIK 0001910644
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $585 since 2026, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BIIB | 19,611 | $5.0M |
Shares reported on the most recent Form 4, priced at the 2026-02-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BIIB | BUY | 2026-02-12 | 2026-02-17 | $195.04 | $585 | -1.8% | -6.0% | -1.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.